#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“We simply don’t have the longitudinal data we need to tell a 16-year-old with confidence what regular cannabis use will do to their developing prefrontal cortex, and that uncertainty should make us cautious in clinical practice, regardless of what the legal status is in their state.”
💭 As cannabis legalization expands across North America, clinicians caring for adolescents face growing uncertainty about developmental risks, particularly given inconsistent surveillance data and variable potency of products in legal markets. The lack of coordinated monitoring systems means that population-level harms may be underestimated or unevenly distributed across communities, making it difficult to counsel patients based on complete epidemiologic evidence. Additionally, individual vulnerability varies significantly based on genetics, concurrent mental health conditions, and timing of use during critical neurodevelopmental windows, complicating risk stratification at the bedside. Clinicians should incorporate regular, non-judgmental cannabis use screening into adolescent visits, remain alert for signs of cannabis use disorder or emerging psychosis, and acknowledge the genuine knowledge gaps when discussing risks with young patients and their families rather than relying on outdated or overstated claims.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: